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G protein-coupled estrogen receptor (GPER) is an estrogen receptor expressed in
the cardiovascular system. G1, a selective GPER ligand, exerts cardiovascular effects
through activation of the PI3K-Akt pathway and Notch signaling in normotensive
animals. Here, we investigated whether the G1/GPER interaction is involved in the
limitation of infarct size, and improvement of post-ischemic contractile function in
female spontaneous hypertensive rat (SHR) hearts. In this model, we also studied
Notch signaling and key components of survival pathway, namely PI3K-Akt, nitric
oxide synthase (NOS) and mitochondrial K+-ATP (MitoKATP) channels. Rat hearts
isolated from female SHR underwent 30 min of global, normothermic ischemia
and 120 min of reperfusion. G1 (10 nM) alone or specific inhibitors of GPER,
PI3K/NOS and MitoKATP channels co-infused with G1, just before I/R, were studied.
The involvement of Notch1 was studied by Western blotting. Infarct size and left
ventricular pressure were measured. To confirm endothelial-independent G1-induced
protection by Notch signaling, H9c2 cells were studied with specific inhibitor, N-[N-
(3,5 difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT, 5 µM), of this
signaling. Using DAPT, we confirmed the involvement of G1/Notch signaling in limiting
infarct size in heart of normotensive animals. In the hypertensive model, G1-induced
reduction in infarct size and improvement of cardiac function were prevented by the
inhibition of GPER, PI3K/NOS, and MitoKATP channels. The involvement of Notch
was confirmed by western blot in the hypertensive model and by the specific inhibitor
in the normotensive model and cardiac cell line. Our results suggest that GPERs
play a pivotal role in mediating preconditioning cardioprotection in normotensive and
hypertensive conditions. The G1-induced protection involves Notch1 and is able to
activate the survival pathway in the presence of comorbidity. Several pathological
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conditions, including hypertension, reduce the efficacy of ischemic conditioning
strategies. However, G1-induced protection can result in significant reduction of I/R
injury also female in hypertensive animals. Further studies may ascertain the clinical
translation of the present results.
Keywords: cardioprotection, preconditioning, H9c2, isolated rat hearts, reperfusion injury salvage kinases,
PI3K/Akt, NOS
INTRODUCTION
The G protein-coupled estrogen receptor (GPR30/GPER) is
expressed in the heart and it mediates non-genomic effects of
estrogen. It has been suggested that GPER activation mediates
beneficial effects in the cardiovascular system, as demonstrated
using pharmacological agonists/antagonists of GPER (Dennis
et al., 2009). In this regard, the synthetic and selective GPER
agonist, G1 (Bologa et al., 2006), has been shown to activate
signaling pathways involved in cardiomyocytes survival, thus
improving cardiovascular function both in normal and stressful
conditions. Yet, the synthetic and selective GPER antagonist,
G15 (Dennis et al., 2009), prevented these beneficial effects
(De Francesco et al., 2013, 2017). To obtain its effect, GPER
cross-reacts with a number of cell signaling systems, including
the epidermal growth factor receptor, the mitogen-activated
protein kinases and the Notch signaling pathway (Pupo et al.,
2016).
In the normotensive rat, GPER activation improves contractile
recovery and limits infarct size in isolated rat hearts following
ischemia/reperfusion (I/R) through a gender-independent and
PI3K-dependent mechanism (Deschamps and Murphy, 2009).
The potential of ischemic preconditioning to reduce I/R injury
has been recognized more than 30 years ago (Hausenloy et al.,
2016). Preconditioning limits I/R injury via multiple pathways.
However, the effectiveness of this cardioprotective intervention
is noticeably reduced in pathological animal models, such as
hypertensive animals (Ferdinandy et al., 2007).
Several data demonstrated that in both normotensive male
and female rodent models, the GPER activation plays a role as
pre- and post-conditioning cardioprotective agent in vitro and
ex vivo (Deschamps and Murphy, 2009; Bopassa et al., 2010;
Deschamps et al., 2010; Li et al., 2015; Feng et al., 2017; Menazza
et al., 2017). These GPER-dependent cardioprotective effects are
displayed by its ability to improve the functional recovery, to
preserve the mitochondrial structural integrity and function and
to reduce mitophagy.
However, the potential of GPER to mediate beneficial effects
in hypertensive conditions has not yet been fully investigated.
In male spontaneously hypertensive rats (SHRs) hearts, we
have reported that the activation of GPER reduced the expression
of apoptotic and fibrotic factors and induced negative inotropic
and lusitropic effects (De Francesco et al., 2013). In these hearts,
GPER induced activation Akt/PKB, ERK1/2, GSK-3β, c-Jun and
endothelial nitric oxide (NO) synthase (eNOS) signaling. Also,
GPER prevents the detrimental cardiac effects of certain anti-
cancer agents like Doxorubicin (De Francesco et al., 2017).
Hence, GPER may represent a novel pharmacological target in
the treatment of some cardiovascular pathologies associated with
stressful conditions, such as hypertension (De Francesco et al.,
2013).
Besides cross-talking with GPER in breast cancer cell
lines (Pupo et al., 2014), Notch signaling pathway plays an
important role in regulating cell death, differentiation, and
angiogenesis (Lubecka et al., 2016). Moreover, it is associated with
cardioprotection. Indeed, Notch signaling pathway activation
reduces I/R injury and modulates cardiac repair after myocardial
infarction (Li et al., 2010). Importantly, Notch drives cell
survival signaling contributing to cardioprotection by ischemic
conditioning protocols in healthy animals (Zhou et al., 2013).
Therefore, we hypothesized that GPER/Notch pathway may be
involved in the cardioprotection mediated by GPER-agonist in
hypertensive female models. To ascertain this hypothesis, we
studied GPER/Notch pathway in the heart of hypertensive model,
firstly using the two synthetic molecules G1 and G15, which act as
selective and potent agonist and antagonist of GPER, respectively.
These allowed to discriminate the selective GPER activation
from the estrogen effects mediated by the classical intracellular
estrogen receptors (ER α/β). In addition, in order to further
explore the mechanism of action GPER-dependent, specific
inhibitors of PI3K/NOS pathway and mitoKATP channels were
used. The Notch involvement was studied by Western blot
analysis. For comparative purpose, we confirmed the role
of GPER/Notch pathway in hearts of normotensive animals
using specif inhibitors of GPER and Notch pathway. To
further analyze a direct cardioprotective effect of GPER agonist,
we studied its effect in an in vitro model of injury: we
subjected rat embryonic-heart derived cardiomyoblasts (H9c2) to
hypoxia/reoxygenation with and without inhibitors of PI3K/NOS
pathway and MitoKATP channels.
MATERIALS AND METHODS
Animals
Female normotensive Wistar rats (n = 25; body weight: 250–
300 g; Harlan Laboratories, Udine, Italy) and Female SHRs
(n = 28; body weight: 250–300; Harlan Laboratories, Udine,
Italy) received humane care in compliance with the Guide for
the Care and Use of Laboratory Animals published by the
United States National Institutes of Health (NIH Publication
No. 85-23, revised 1996). Two normotensive Wistar rat hearts
and one SHR heart were discarded due to their very low left
ventricular developed pressure or other technical issues after
connection to the perfusion line. In accordance with the Italian
law in force (DL n. 116, January 27, 1992), regarding animal
protection, the scientific project has been approved by the Italian
Ministry of Health (Rome, Italy). All animals were identically
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housed under controlled light and temperature conditions with
access to food and water ad libitum. SHR female rats, used in this
paper for hemodynamic studies, are part of a set of hypertensive
animals whose male counterpart was employed in previous works
(De Francesco et al., 2013; Pasqua et al., 2015). The basal blood
pressure of female animals (recorded before experiments by the
tail-cuff method) displayed the same trend of male rats (data not
shown).
Experimental Models
Isolated Perfused Heart
The methods were similar to those previously described (Penna
et al., 2009, 2011; Pasqua et al., 2015). Briefly, each animal
was heparinized (800 U/100 g b.w., i.m.) and after 10 min
rats were anesthetized with i.p. injection of ethyl carbamate
(2 g/kg rat), then hearts were rapidly excised and immediately
arrested in ice-cold buffered Krebs–Henseleit solution (KHS)
for subsequent aorta cannulation. Hearts were then perfused at
constant retrograde flow (12 ml/min) and constant temperature
of 37◦C. Perfusion medium was a modified Krebs–Henseleit
Solution (KHS; pH 7.4) gassed with 95% O2 and 5% CO2
containing (in mM): 113.0 NaCl; 4.7 KCl; 1.2 MgSO4; 25.0
NaHCO3; 1.2 KH2PO4; 1.8 CaCl2; 11.0 glucose; 1.1 mannitol; 5.0
Na-pyruvate (Pasqua et al., 2015). A water-filled latex balloon was
connected to a pressure transducer (BLPR, WRI, Inc., Saratota,
FL, United States) and pushed into the left ventricle (LV) through
the mitral valve. Another pressure transducer connected with
perfusion cannula was used to measure coronary pressure (CP).
The developed left ventricular pressure (dLVP; mmHg, index
of contractile activity) and the left ventricular end diastolic
pressure (LVEDP; mmHg, index of contracture) were measured
to evaluate cardiac function. The LVEDP was set to obtain
a 5–8 mmHg pressure. Cardiac performance was recorded by
using the PowerLab data acquisition system. Parameters were
quantified by using Chart Software (ADInstruments, Oxford,
United Kingdom) (Pasqua et al., 2015).
After stabilization, reference parameters were recorded and
each heart was assigned in random order to one of the following
experimental groups described below (Figure 1A).
Normotensive Heart Model
Four groups of hearts isolated from normotensive animals were
subjected to the following protocols:
(1) Sham group (n = 3): hearts were stabilized for 30 min and
then subjected to 150 min of perfusion only.
(2) I/R group (n = 8): after a 30 min stabilization period,
the perfusion was completely stopped (global no-flow
ischemia) for a duration of 30 min. Thereafter, hearts were
reperfused for 120 min.
(3) GPER agonist G1 (G1) group (n = 7): hearts were
pre-treated with G1 (10 nM), a GPER selective agonist
for 20 min. Thereafter the hearts were subjected to I/R
protocol, as above (De Francesco et al., 2013).
(4) G1+Notch inhibitor group (n = 5): hearts were
pre-treated with a co-infusion of G1 and a selective
inhibitor of Notch pathway, namely N-[N-(3,5
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester (DAPT, 5 µM) (Boccalini et al., 2015), and then four
hearts were subjected to I/R.
Hypertensive Heart Model
In the following groups: Sham (n = 3), I/R (n = 3), G1 (n = 5),
hearts isolated from female SHR were subjected to the protocols
described above for normotensive animals.
Moreover, to deepen the signaling pathway involved in
protection, the following groups were studied in the hypertensive
model:
(8) G1+G15 group (n = 4): hearts were pre-treated with a
co-infusion of the selective GPER agonist, G1 (10 nM),
and the selective GPER antagonist G15 (100 nM) (De
Francesco et al., 2013) and then subjected to I/R.
(9) G1+ WT group (n = 4): after stabilization, hearts were
pretreated with a co-infusion of G1 (10 nM) and WT
(100 nM) (Deschamps and Murphy, 2009; Penna et al.,
2017).
(10) G1+L-NIO group (n = 4): after stabilization, hearts were
pretreated with a co-infusion of G1 (10 nM) and L-NIO
(10 µM) (El-Mas et al., 2009; De Francesco et al., 2013).
(11) G1+5HD group (n = 4): after stabilization, hearts were
pretreated with a co-infusion of G1 (10 nM) and 5HD
(100 µM) (Ajmani et al., 2011; Perrelli et al., 2013).
G1 concentration was selected on the basis of previous
experiments (De Francesco et al., 2013).
The concentration for each pharmacological inhibitor was
selected on the basis of preliminary dose–response curves,
and according to the literature, as the first dose that did not
significantly affect cardiac performance (De Francesco et al.,
2013; Perrelli et al., 2013; Boccalini et al., 2015; Penna et al.,
2017). The stability of the preparations was previously assessed by
measuring each variable considered every 10 min. The stability of
the preparation was on average 180 min.
In line with 3R principle for more ethical use of animals, we
used less than four animals in those groups in which we have
previous evidence of similar results (Penna et al., 2009, 2010,
2012; Rocca et al., 2018).
Cell Culture
The cardiac myoblast H9c2 cell line (ATCC, CRL-1446) was
maintained in DMEM supplemented with 10% heat-inactivated
fetal bovine serum (FBS) and 1% (v/v) streptomycin/penicillin in
a humidified incubator at 37◦C under 5% CO2 air prior to use
(Hescheler et al., 1991).
In all sets of experiments, 80% confluent flasks were detached,
counted in the Burker chamber and plated in 96 wells plate at a
density of 5000 cells/well. Cells were then left for 24-h in standard
culture conditions before applying the hypoxia/reoxygenation
(H/R) protocols.
Hypoxia/Reoxygenation (H/R) Protocol
In this set of experiments, performed for comparative purposes,
cells were cultured in normoxic conditions (21% O2 and 5% CO2)
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FIGURE 1 | Timeline of experimental protocols. (A) Protocols of ischemia/reperfusion (I/R) in isolated rat hearts and Sham group. G1 was given for 20 min before
ischemia and inhibitors (DAPT, inhibitor of Notch or G15, selective GPER antagonist or Wortmannin, a specific inhibitor of PI3K activity or L-N5-(1-iminoethyl)ornithine
(L-NIO), a specific inhibitor of nitric oxide synthase (NOS), or 5-hydroxydecanoate (5HD), a specific inhibitor of mitochondrial ATP-sensitive potassium [MitoK(ATP)])
were given 5 min before G1 and was stopped at the end of the 20 min of infusion of G1. (B) Protocols of normoxia and hypoxia/reoxygenation (H/R) in H9c2 cells.
G1 or G1+DAPT or DMSO were given before hypoxia/reoxygenation protocol. MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye is used as
colorimetric assay for assessing cell metabolic activity, reflecting the number of viable cells present. IB, ischemic buffer.
or in conditions of Hypoxia/Reoxygenation (1% O2 and 5% CO2
for 2 h, and subsequently 21% O2 and 5% CO2 for 1 h).
As Normoxia (N) we considered cell survival studied during
standard H9c2 culture conditions.
As Hypoxia/Reoxygenation (H/R) we considered cell survival
studied with for 2-h and a subsequent reoxygenation for 1-h.
H/R protocol was obtained in a hypoxic chamber (INVIVO2
200, Belsar, Varese, Italy) and with an “Ischemic Buffer” (IB)
containing (in mM): 137 NaCl; 12 KCl; 0.49 MgCl2; 0.9 CaCl2;
4 HEPES; 20 sodium lactate (pH 6.2) (Yin et al., 2013).
Before hypoxia, cells were pre-treated with G1 (10 nM) (De
Francesco et al., 2013), or G1+ DAPT, (5 µM); (Boccalini et al.,
2015) dissolved in DMEM-2% FBS in normoxic conditions and
in IB in hypoxic conditions. Experimental groups, recapitulated
in Figure 1B, are as follows:
(a) Control Groups, untreated cells cultured in normoxic
conditions (H9c2-N); untreated cells subjected to H/R
(H9c2-H/R).
(b) G1 Group, cells pre-treated with G1 (10 nM) and then
subject to H/R protocol (H9c2_G1_H/R).
(c) G1+DAPT Group, cells pre-treated with G1 +
DAPT (5 µM) and then subject to H/R protocol
(H9c2_G1+DAPT_H/R).
(d) DAPT Group, cells pre-treated with DAPT and then
subject to H/R protocol (H9c2_DAPT_H/R).
(e) DMSO Group, cells pre-treated with DMSO (0.1%) and
then subject to H/R protocol (H9c2_DMSO_H/R).
Assessment of Myocardial Injury
Infarct mass was measured as usual in our laboratories (Penna
et al., 2014; Pasqua et al., 2015). In short, the hearts were detached
from the perfusion system at the end of the reperfusion and
the left ventricles cut into circumferential sections about 2 mm
thick. The heart slices were incubated for 20 min at 37◦C in a
0.1% nitro-blue tetrazolium solution with phosphate buffer. The
non-colored necrotic tissue was carefully separated from the vital
tissue colored by an observer who was unaware of the studied
protocol. The necrotic mass was gravimetrically weighed and
expressed as a percentage of total left ventricular mass that was
considered to be a risk area for global ischemia (Penna et al.,
2014).
MTT Assay
At the end of all experiments, cell viability was assessed
using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) kit (Pasqua et al., 2015). The absorbance was
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measured at 570 nm using a microplate reader and the results
were expressed as a percentage of control.
Western Blotting and Densitometric Analysis
Immunoblot procedures and analyses were conducted as
previously described (Rocca et al., 2018). Immediately after
the hearts had undergone the specific protocols described
above (Sham, I/R, I/R+DAPT, I/R+G1, I/R+G1+DAPT for
normotensive group and Sham, I/R, G1, and G1+G15 for
hypertensive group), the cardiac apices were frozen in liquid
nitrogen before being stored at −80◦C until protein extraction
(Penna et al., 2014). Myocardial tissues of the above groups
were homogenized in a frozen RIPA lysis buffer (Sigma-Aldrich,
St. Louis, MO, United States) containing a mixture of protease
inhibitors (1 mM of aprotinin, 20 mM of phenylmethylsulfonyl
fluoride, and 200 mM of sodium orthovanadate). Subsequently,
myocardial homogenates were centrifuged at 15,000 × g for
25 min at 4◦C for debris removal. Protein concentration was
assessed using a Bradford reagent following the procedure
described by the manufacturer (Sigma-Aldrich, St. Louis, MO,
United States).
30 µg of total protein were separated on 10% SDS-
PAGE gel [for β-actin, phospho-protein kinase B (p-Akt),
total Akt (t-Akt), total Notch1, and cleaved Notch1)] or
8% Gel SDS-PAGE [for phospho-endothelial NOS (p-eNOS)
and total eNOS (t-eNOS)], subjected to electrophoresis and
transferred to polyvinyl-fluoride membranes (PVDFs). The non-
specific binding was blocked by incubating the membranes
with a buffered saline solution (TBS)/Tween 0.1%, pH 7.6
(TBST), containing 5% of fat-free dried milk and 0.5% BSA,
for 1 h at room temperature. The PVDF membranes were
incubated overnight at 4◦C with a goat polyclonal antibody
for Notch1 (C-20; Santa Cruz, CA, United States), which
recognizes the carboxy-terminal of the Notch1 receptor, to
detect the precursor of Notch1 (Notch1-PR, 250 kDa) (Caliceti
et al., 2013; Fortini et al., 2017) or rabbit monoclonal
antibody against cleaved Notch (Cell Signaling Technology,
Inc., Danvers, MA, United States), which detects endogenous
levels of intracellular Notch1 domain (NICD) when released
from the cleavage between Gly1753 and Val1754. Samples were
also incubated with rabbit polyclonal antibody against p-Akt,
Akt, or eNOS (Santa Cruz Biotechnology, Inc., Dallas, TX,
United States), with monoclonal goat antibody against p-eNOS
(Santa Cruz Biotechnology, Inc., Dallas, TX, United States),
with mouse monoclonal antibody against β-actin (Santa Cruz
Biotechnology, Inc., Dallas, TX, United States), or with
mouse monoclonal antibodies to GAPDH (Cell Signaling
Technology, Inc., Danvers, TX, United States). The antibodies
were diluted 1:1000 in TBST containing 5% BSA (TBSTM).
Antibodies against Akt, eNOS, GAPDH, and β-actin were
used as loading controls. After washing them with TBST
three times, the membranes were incubated for about 1 h at
room temperature with antibodies conjugated with secondary
peroxidase (1:1000) in TBSTM. Immunodetection was done
using the enhanced chemiluminescence kit ECL PLUS (GE
Healthcare, Amersham, United Kingdom). Autoradiographs
were obtained by exposing the membrane films to X-ray
(Hyperfilm ECL, Amersham, United Kingdom). We then
proceeded to digitize the immunoblots that were subjected to
densitometric analysis of the bands. The analysis was performed
by evaluating the areas and the intensity of the pixels represented
by 256 values of Gray (0 = white; 256 = black). As usual, the
background has been subtracted. The analyses were performed
using NIH IMAGE 1.6 (National Institutes of Health, Bethesda,
MD, United States).
Chemicals
1-[4-(-6-Bromobenzol[1,3]diodo-5-yl)-3a,4,5,9-btetrahydro-3H-
cyclopenta[c-]quinolin8yl]ethanone (G-1) and (3aS,4R,9bR)
-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta[c]
quinolone (G15) were from Tocris Bioscience, distributed by
Space (Milan, Italy). Wortmannin (WT), a specific inhibitor of
PI3K activity, L-N5-(1-iminoethyl)ornithine (L-NIO), a specific
inhibitor of nitric oxide synthase (NOS), 5-hydroxydecanoate
(5HD), a specific inhibitor of MitoK(ATP) channels, and
DAPT, a γ-secretase complex inhibitor, were purchased
from Sigma-Aldrich (Milan, Italy). Reagents were dissolved
in dimethylsulfoxide (DMSO). Preliminary experiments
showed that the presence of equivalent amounts of DMSO in
Krebs–Henseleit solution (KHs) did not modify basal cardiac
performance. All drug-containing solutions were freshly
prepared just before the experiments.
Statistical Analysis
All data were reported as mean± SEM and analyzed by one-way
analysis of variance (ANOVA). Non-parametric Newman–Keuls
multiple comparison test (for post-ANOVA comparisons) was
used for western blot and hemodynamic analyses. Differences at
∗p = < 0.05, ∗∗p = < 0.01, ∗∗∗p = < 0.001, ∗∗∗∗p = < 0.0001
were considered statistically significant. The statistical analyses
were carried out using GraphPad Prism5.
RESULTS
The cardioprotective effects of G1 in isolated heart models
were studied by comparing the effects elicited by I/R protocols
with those induced by the GPER-agonist, G1, used as a pre-
conditioning factor (PreC).
Normotensive Rat Model
Cardioprotective Effect of GPER
Infarct size reduction by G1 preconditioning
Here we confirmed the cardioprotective effect of GPER estrogen
agonist, G1 (Bopassa et al., 2010; Li et al., 2015; Menazza et al.,
2017). In particular, using an isolated rat heart model, infarct size
was reduced from 63 ± 4% of risk area in I/R group to 48 ± 2%
of risk area in G1 pretreated hearts (p< 0.01) (Figure 2A).
Involvement of Notch pathway in cardioprotective effect of
GPER
The G1 cardioprotective effect was nullified by treatment with
DAPT, an inhibitor of the γ-secretase, the enzyme required for
the Notch1 cleavage and activation, co-infused with G1 (infarct
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FIGURE 2 | Cardioprotective effects of G1 in normotensive female rats were abolished by Notch1 inhibitor. (A) Infarct size. The amount of necrotic tissue measured
after I/R protocols (30-min global ischemia and 120-min reperfusion) is reported as percent of the left ventricle mass (LV; % IS/LV) for I/R (n = 8), G1 (n = 7), and
G1+DAPT groups (n = 4). (B) Western blotting (upper panel) of rat heart homogenates electrophoresed and immunoblotted with Notch1 C-20 antibody. GAPDH was
used as loading control. Histograms (bottom panel) represent the ratio of densitometric analysis of protein/loading control normalized to Sham. The level of
Notch1-PR was reduced in heart after I/R injury, compared to Sham group, indicating activation of Notch1, activation further increased by G1 treatment. DAPT
treatment increased Notch1-PR protein level in heart subjected to I/R injury, both in the presence and absence of G1, suggestive of an inhibition of Notch1
activation. ∗∗∗∗p < 0.0001 IR vs. IR+DAPT and IR+G1 vs. IR+DAPT; ∗∗∗p < 0.001 IR+G1 vs. SHAM; ∗∗p < 0.01 IR vs. SHAM; ∗p < 0.05 IR+DAPT vs. SHAM and
IR vs. IR+G1.
size 68 ± 1%; p < 0.05 spect to G1 group; p = NS respect
to I/R group) (Figure 2A). To confirm the involvement of
Notch downstream of GPER during I/R, we performed Western
blot analyses on heart homogenates from different treatment
groups and showed that I/R induces the activation of Notch1,
as indicated by the reduction of the precursor form (PR) of
the receptor (Figure 2B). G1 treatment further induced Notch1
processing and this effect was blocked by DAPT (Figure 2B). The
full unedited gel is showed in the Supplementary Figure 1.
Hypertensive Rat Model
After we demonstrated the involvement of the GPER/Notch
pathway in normotensive hearts, we focused on studying the G1
cardioprotective pathway in the hypertensive model in the detail.
Cardioprotective Effect of GPER
Infarct size is reduced by G1 preconditioning
Infarct size was reduced from 80± 9.6% of risk area in I/R group
to 42 ± 2.5% of risk area in G1 pretreated hearts (p < 0.01)
(Figure 3A). Moreover, when G1 was co-infused with the direct
inhibitor of GPER, G15, hearts showed an infarct size similar to
that found for I/R group (Figure 3A).
Post-ischemic diastolic and systolic functions are improved
by G1 preconditioning
The effects mediated by G1 on diastolic and systolic functions
were analyzed as previously described (De Francesco et al., 2013).
It is known that an increase in post-ischemic left ventricular
end-diastolic pressure (LVEDP) of 4 mmHg or more above
the pre-ischemic level indicates an important index of cardiac
contracture. The 30 min ischemia and the subsequent reperfusion
caused a sustained increase in LVEDP in I/R group (Figure 3B)
(Pagliaro et al., 2003; Pasqua et al., 2015). Conversely, the
preconditioning with G1 was able to abolish the contracture
(Figure 3B), indicating that G1 significantly reduces the heart
damage after I/R. Similar to the reduction in infarct size, the
limitation of contracture was suppressed when G1 was co-infused
with the direct inhibitor of GPER, G15.
Systolic function was evaluated by the level of dLVP recovery
during reperfusion (i.e., inotropic index). SHR hearts from I/R
group showed a limited dLVP recovery, while G1, administered
before ischemia induction, significantly improved this function
(Figure 3C). The co-infusion with the GPER-antagonist, G15,
abolished the post-systolic recovery, indicating that G1 exerts a
selective action on its receptor.
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FIGURE 3 | Cardioprotective effects of G1 in Hypertensive Female Rats (SHR) were abolished by GPER antagonistic specific inhibitor. (A) Infarct size. The amount of
necrotic tissue measured after I/R protocols (30-min global ischemia and 120-min reperfusion) is reported as percentage of the left ventricle mass (LV; % IS/LV) for
I/R (n = 3), G1 (n = 5), and G1+G15 groups (n = 4). (B,C) LVEDP and dLVP variations at the end of reperfusion. Data are expressed as changes of dLVP and LVEDP
values (mmHg) at the end of the 120-min of reperfusion for I/R (n = 3), G1 (n = 5), and G1+G15 groups (n = 4). Changes were evaluated as mean ± SEM. Significant
difference (one-way ANOVA, Newman–Keuls test): ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
G1-induced infarct size limitation and improvement of
post-ischemic contractile recovery is mediated by
PI3K/NO/mKATP channels
In order to estimate the mechanism of action by which G1 exerted
the cardioprotective effects in SHR hearts, the isolated and
perfused hearts were co-treated with G1 plus specific inhibitors
of survival signaling pathways involved in cardioprotection (i.e.,
WT to block PI3K, L-NIO to inhibit NOS, and 5HD to antagonize
MitoKATP channels). Figure 4 shows that all inhibitors abrogate
the beneficial effects of G1 on all analyzed parameters. Indeed,
G1-dependent reduction of infarct size was abolished in hearts
co-treated with all the cardioprotective signaling antagonists
(Figure 4A). Moreover, these inhibitors limited the post-ischemic
systolic recovery elicited by G1, as demonstrated by the low values
of dLVP reached at the end of reperfusion (Figure 4B). Similarly,
the contracture limitation induced by G1 was suppressed in the
presence of the above blockers (data not shown).
Effects of G1 as preconditioning agent on Notch and
PI3K/Akt/NOS pathways
The involvement of the kinase Akt, the endothelial form of NOS
(eNOS) and cleaved Notch1 in the G1-induced cardioprotection
was evaluated by Western blot analysis. Representative bands and
densitometric analyses for these markers are shown in Figure 5.
In post-ischemic SHR hearts preconditioned with G1, the levels
of phosphorylated Akt (Figure 5A) and eNOS (Figure 5B), and
the levels of cleaved Notch1 (Figure 5C) were significantly higher,
compared to the control counterparts I/R. On the contrary,
p-Akt, p-eNOS, and cleaved Notch1 expression levels were
significantly reduced by G15 co-treatment (Figure 5). The full
unedited gels are showed in the Supplementary Figures 2–4,
respectively.
H9c2 Hypoxia/Reoxygenation (H/R) Protocol
G1 induces cardiac cell protection via Notch signaling
pathway
In Figure 6 the effects of H/R in G1 treated cells and after
G1 + DAPT pre-treatment compared to normoxic and hypoxic
controls (H9c2_N and H9c2_H/R) are reported. DAPT abolished
the protective effect induced by G1 pre-treatment against cell
death induced by H/R protocol (p< 0.001 vs. H9c2_H/R). These
results suggest that G1 is an important protective factor during
hypoxia able to trigger the Notch1 signaling in cardiac cells.
DISCUSSION
In this study, we confirm that the cardioprotective role of GPER
is Notch1 dependent in normotensive female rats. Importantly,
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FIGURE 4 | Cardioprotective effects of G1 in Hypertensive Female Rats (SHR) were abolished by specific inhibitors of PI3K/Akt-eNOS-MitoKATP channels.
(A) Infarct size. The amount of necrotic tissue measured after I/R protocols (30-min global ischemia and 120-min reperfusion) is reported as percentage of the left
ventricle mass (LV; % IS/LV) for G1 (n = 5) and G1+inhibitors (WT, L-NIO, and 5HD) groups (n = 4). (B) dLVP variations. Data are expressed as changes of dLVP
values (mmHg) at the end of the 120-min of reperfusion for G1 (n = 5) and G1+inhibitors (WT, L-NIO, and 5HD) groups (n = 4). Changes were evaluated as
mean ± SEM. Significant difference (one-way ANOVA, Newman–Keuls test): ∗∗p < 0.01, ∗∗∗p < 0.001.
FIGURE 5 | Effects of G1 given as preconditioning agent on Notch, PI3K/Akt/NOS Pathway Western Blot analysis of (A) p-Akt, (B) p-eNOS, and (C) cleaved Notch1
expression in cardiac extracts of Sham, I/R, G1, and G1+G15 groups (n = 3 hearts/group). Histograms represent the ratio of densitometric analysis of
protein/loading control. Significant difference (one-way ANOVA, Newman–Keuls test): ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
the preconditioning activation of GPER with the selective agonist,
G1, significantly reduces I/R injury in the hypertensive female
rat heart model. Moreover, in this model G1 is able to activate
PI3K/Akt/NOS/MitoKATP channel and Notch1 pathways. The
protective effect induced by GPER activation is mediated by
Notch1, as also suggested by reduction of cell mortality in the
H9c2 model. These results obtained in cardiac cells suggest
that the G1 protective effects do not require an endothelial
mediation.
The main novel finding of the present study is that the
activation of GPER by its selective ligand, G1, protects the heart
against I/R injury not only in a normotensive model but also in a
model of comorbidity, namely female SHR. In these hypertensive
female rats, Notch1 signaling and PI3K/NOS/MitoKATP channel
pathways are activated by preconditioning treatment with the
GPER agonist G1.
It is well-known that estrogens act through two nuclear
receptors: estrogen receptor-alpha (ER-α) or estrogen receptor-
beta (ER-β); yet, a third, membrane-bound receptor G protein-
coupled estrogen receptor (GPER), has been discovered. GPER
has been shown to bind estrogen with high affinity (Zimmerman
et al., 2016) and to be localized in the different internal and
external cellular localization (Bopassa et al., 2010).
G1 demonstrated high specificity to GPER with little to no
binding to other estrogen receptors, either ER-β or ER-α.
Treating acutely animals or perfusing the hearts with 17
beta-estradiol (E2), it has been demonstrated that E2/GPER
interaction reduces I/R injury (Deschamps and Murphy, 2009).
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FIGURE 6 | Cell vitality in Normoxia (N) and Hypoxia/Reoxygenation (H/R)
conditions. Data are presented as percentage variation with respect to mean
value of cell count in normoxia, in control group. Treatment with G1 or G1 in
the presence of Notch inhibitor (DAPT) in H/R conditions. Data of control I/R
groups with DAPT and DMS are also reported. For acronyms see the text.
∗∗∗p < 0.001 vs. H9c2_N; ∗∗∗p < 0.001 H9c2_G1 vs. all other H/R
conditions.
Moreover, in normotensive condition, the protective effects
induced by acute GPER activation induce a remarkable
cardioprotection by improving cardiac functional recovery, by
reduction the infarct size, and by inhibiting the mPTP opening
in isolated rodents hearts exposed to I/R stress (Deschamps and
Murphy, 2009; Bopassa et al., 2010; Deschamps et al., 2010; Li
et al., 2015; Feng et al., 2017; Menazza et al., 2017). These studies
demonstrated that the protective effect of GPER is mediated
by the Erk pathway activation, increased superoxide dismutase
(SOD), and ATP and decreased the tumor necrosis factor alpha
(TNFα) expression level, effects that were also observed in a
cardiac cell model subjected to simulated I/R protocols (Li et al.,
2015). These results are in agreement with the findings of our
study.
As post-conditioning agent, Feng et al. (2017) reported that
the cardioprotection of GPER displays via the protection of
the mitochondrial structural integrity; moreover, the activation
of MEK/Erk signaling leads to the reduction of mitochondrial
protein ubiquitination and protection of mitochondrial
membrane potential dissipation; these alterations are normally
responsible of mitophagy, ROS generation and apoptosis
typically of I/R damage (Feng et al., 2017).
Notch signaling pathway seems indispensable for functional
activities controlling tissue formation in cardiogenesis
(Kratsios et al., 2010). Moreover, it is an important cell–cell
communication system and its activation after the damage
has been demonstrated in several tissues (Kratsios et al., 2010;
Rizzo et al., 2017). It has been reported that Notch signaling
plays a regulatory role in adult cardiac damage and in the
cardioprotection preserving cardiac function after ischemia.
FIGURE 7 | Representative scheme of intracellular pathway involved in the
GPER/Notch1 cardioprotection.
In particular, this Notch activation supports cell survival via
PI3K induction (Gude et al., 2008). Indeed, in the control
of NOS system by Notch1, PI3K/Akt may act as a mediator
of eNOS phosphorylation. The blockade of Notch reduced
phosphorylation of eNOS and Akt as assessed by western
blots in the reperfused hearts (Pei et al., 2013). Several studies
report impairment of endothelial Notch signaling in pathological
conditions, e.g., heart failure (Pannella et al., 2016), inflammation
(Fortini et al., 2017), and dyslipidemia (Briot et al., 2015). Notch
signaling can be also impaired by anti-cancer drugs and this
may represent an unwanted side effect (Rizzo et al., 2015). The
relation of GPER/Notch is demonstrated in other cellular models
(Pupo et al., 2016). In particular, we have recently observed
that certain non-genomic estrogenic signals are mediated by
a functional crosstalk between the Notch signaling pathway
and GPER (Pupo et al., 2016). Moreover, we reported that this
Notch/GPER crosstalk is involved in proliferative and migratory
effects by estrogen, in breast cancer cells and cancer-associated
fibroblasts (Pupo et al., 2014).
Here, for the first time, Notch signaling, nitric oxide, and
cell survival pathway are linked to preconditioning protection by
GPER activation (Figure 7).
Estrogens are hormones regulating physiological and
pathological processes in both women and men. Endogenous
estrogens affect importantly cardiovascular homeostasis in
pre-menopausal women and interfere with the development of
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hypertension and coronary artery disease. Indeed, the gender
differences in cardiovascular risk are surely correlated to
hormonal specificity. The estrogens cardioprotective effects are
widely reported in several animal and human studies; they are
mostly mediated through ERα and/or ERβ, both expressed in
the heart and involved in regulating cardioprotection, both in
genomic and non-genomic mechanisms (Mendelsohn and Karas,
2005; Wang et al., 2006, 2009; Deschamps et al., 2010).
In addition to the classic ERs, the role exerted by GPER in
acute cardioprotection and in the modulation of cardiovascular
function is increasingly consolidating (Deschamps et al., 2010).
Our results support the possibility that acute pre-ischemic
activation of GPER might protect female hypertensive animals
against I/R injury. These results may pave the way for protective
approaches in models with risk factors and comorbidities, which
are much needed to translate successful animal experiments on
cardioprotection beyond that by reperfusion to clinical practice.
CONCLUSION
Here, we have shown that GPER plays a pivotal role in mediating
preconditioning cardioprotection in both normotensive
and hypertensive conditions. This protection requires the
involvement of Notch-1 in cardiac cells and is mediated by
PI3K/NOS/MitoKATP channels.
CLINICAL PERSPECTIVES
The pathways here studied may represent novel targets
and are particularly intriguing for the advancement in
the field of cardioprotection, considering the paucity of
studies in female hearts. These results may contribute to
better understand the preconditioning GPER protection
following ischemia/reperfusion stress in the normotensive and
hypertensive heart, an important target tissue for estrogen-
mediated signaling. Additionally, the present study may provide
more insights for the potential development of a therapy
application based on a selective transmembrane estrogen
receptor modulator able to induces cardioprotection, without
affecting the cancer risk.
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